These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 16924054)

  • 1. An illustrative case of Muir-Torre syndrome: contribution of immunohistochemical analysis in identifying indicator sebaceous lesions.
    Marazza G; Masouyé I; Taylor S; Prins C; Gaudin T; Saurat JH; French LE
    Arch Dermatol; 2006 Aug; 142(8):1039-42. PubMed ID: 16924054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Muir-Torre syndrome among patients with sebaceous tumors and keratoacanthomas: role of clinical features, microsatellite instability, and immunohistochemistry.
    Ponti G; Losi L; Di Gregorio C; Roncucci L; Pedroni M; Scarselli A; Benatti P; Seidenari S; Pellacani G; Lembo L; Rossi G; Marino M; Lucci-Cordisco E; Ponz de Leon M
    Cancer; 2005 Mar; 103(5):1018-25. PubMed ID: 15662714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Muir-Torre syndrome: Diagnostic and screening guidelines.
    Jones B; Oh C; Mangold E; Egan CA
    Australas J Dermatol; 2006 Nov; 47(4):266-9. PubMed ID: 17034469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous sebaceous neoplasms as markers of Muir-Torre syndrome: a diagnostic algorithm.
    Abbas O; Mahalingam M
    J Cutan Pathol; 2009 Jun; 36(6):613-9. PubMed ID: 19515040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Muir-Torre syndrome.
    Lachiewicz AM; Wilkinson TM; Groben P; Ollila DW; Thomas NE
    Am J Clin Dermatol; 2007; 8(5):315-9. PubMed ID: 17902735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Muir-torre syndrome with intriguing squamous lesions: a case report and review of the literature.
    Nishizawa A; Nakanishi Y; Sasajima Y; Yamazaki N; Yamamoto A
    Am J Dermatopathol; 2006 Feb; 28(1):56-9. PubMed ID: 16456327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Muir-Torre syndrome caused by partial duplication of MSH2 gene by Alu-mediated nonhomologous recombination.
    Yanaba K; Nakagawa H; Takeda Y; Koyama N; Sugano K
    Br J Dermatol; 2008 Jan; 158(1):150-6. PubMed ID: 17941949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards identification of hereditary DNA mismatch repair deficiency: sebaceous neoplasm warrants routine immunohistochemical screening regardless of patient's age or other clinical characteristics.
    Orta L; Klimstra DS; Qin J; Mecca P; Tang LH; Busam KJ; Shia J
    Am J Surg Pathol; 2009 Jun; 33(6):934-44. PubMed ID: 19342947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microsatellite instability and immunostaining for MSH-2 and MLH-1 in cutaneous and internal tumors from patients with the Muir-Torre syndrome.
    Machin P; Catasus L; Pons C; Muñoz J; Conde-Zurita JM; Balmaña J; Barnadas M; Martí RM; Prat J; Matias-Guiu X
    J Cutan Pathol; 2002 Aug; 29(7):415-20. PubMed ID: 12139636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MSH-2 and MLH-1 protein expression in Muir Torre syndrome-related and sporadic sebaceous neoplasms.
    Morales-Burgos A; Sánchez JL; Figueroa LD; De Jesús-Monge WE; Cruz-Correa MR; González-Keelan C; Nazario CM
    P R Health Sci J; 2008 Dec; 27(4):322-7. PubMed ID: 19069357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extraocular sebaceous carcinoma in a patient with Muir-Torre syndrome.
    Harrington CR; Egbert BM; Swetter SM
    Dermatol Surg; 2004 May; 30(5):817-9. PubMed ID: 15099333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The tip of the iceberg: multiple cutaneous sebaceous tumor in colon cancer. Muir-Torre syndrome--case report].
    Herr G; Szenes M; Hohl G; Vinkler ME; Tüske G; Horváth J; Nagy G; Tihanyi M; Széll M; Nagy N; Gasztonyi B
    Orv Hetil; 2015 Jun; 156(24):979-84. PubMed ID: 26051134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunosuppression and sebaceous tumors: a confirmed diagnosis of Muir-Torre syndrome unmasked by immunosuppressive therapy.
    Landis MN; Davis CL; Bellus GA; Wolverton SE
    J Am Acad Dermatol; 2011 Nov; 65(5):1054-1058.e1. PubMed ID: 21550136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Multiple sebaceous tumors with colon cancer--Muir-Torre syndrome].
    Vajda A; Scharrer K; Baló-Banga JM
    Orv Hetil; 2003 May; 144(20):985-9. PubMed ID: 12830729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical follow-up and presence of visceral tumors in 12 patients with sebaceous gland tumors].
    Mercader P; García-Melgares ML; Roche E; Sánchez-Carazo JL; Alegre-de Miquel V
    Actas Dermosifiliogr; 2008 Sep; 99(7):532-9. PubMed ID: 18682166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sebaceous gland adenoma of the tarsal conjunctiva in a patient with Muir-Torre syndrome.
    Font RL; Rishi K
    Ophthalmology; 2003 Sep; 110(9):1833-6. PubMed ID: 13129885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of microsatellite instability in unselected sebaceous gland neoplasias and hyperplasias.
    Kruse R; Rütten A; Schweiger N; Jakob E; Mathiak M; Propping P; Mangold E; Bisceglia M; Ruzicka T
    J Invest Dermatol; 2003 May; 120(5):858-64. PubMed ID: 12713593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemistry screening of sebaceous lesions for Muir-Torre syndrome in a 26-year period in a Mexican population.
    Archer-Dubon C; Alvarez-Zavala B; Reyes E; Orozco-Topete R
    Dermatol Online J; 2008 Dec; 14(12):1. PubMed ID: 19265614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Muir-Torre syndrome: a case report and review of the literature.
    Pettey AA; Walsh JS
    Cutis; 2005 Mar; 75(3):149-55. PubMed ID: 15839358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MSH-6: extending the reliability of immunohistochemistry as a screening tool in Muir-Torre syndrome.
    Chhibber V; Dresser K; Mahalingam M
    Mod Pathol; 2008 Feb; 21(2):159-64. PubMed ID: 18065960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.